Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Xalatan
|
| gptkbp:class |
prostaglandin analogs
|
| gptkbp:clinical_trial |
studies on efficacy
studies on safety |
| gptkbp:clinical_use |
gptkb:ocular_hypertension
treatment of elevated intraocular pressure |
| gptkbp:contraindication |
hypersensitivity to latanoprost
active intraocular inflammation history of herpetic keratitis |
| gptkbp:dosage_form |
one drop in the affected eye(s) once daily
|
| gptkbp:effective_date |
gptkb:1996
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
gptkb:cream
|
| gptkbp:formulation |
0.005% solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xalatan
|
| gptkbp:ingredients |
gptkb:latanoprost
|
| gptkbp:interacts_with |
other eye medications
systemic medications |
| gptkbp:invention |
patented
|
| gptkbp:lifespan |
17 minutes
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:marketed_as |
gptkb:Europe
gptkb:Australia gptkb:Canada gptkb:United_States |
| gptkbp:packaging |
gptkb:bottle
dropper bottle |
| gptkbp:patient_population |
storage instructions
instructions for use disposal instructions missed dose instructions side effects information |
| gptkbp:pharmacokinetics |
metabolized in the liver
increases outflow of aqueous humor |
| gptkbp:previous_name |
gptkb:latanoprost
|
| gptkbp:provides_guidance_on |
used in combination therapy
recommended for first-line therapy |
| gptkbp:requires |
prescription only
|
| gptkbp:route_of_administration |
ophthalmic
|
| gptkbp:shelf_life |
2 years
|
| gptkbp:side_effect |
dry eyes
blurred vision eye irritation visual disturbances conjunctival hyperemia eyelash growth increased pigmentation of the iris macular edema eyelash changes cystoid macular edema periorbital skin pigmentation |
| gptkbp:storage |
room temperature
|
| gptkbp:used_for |
gptkb:Ophthalmology
|
| gptkbp:bfsParent |
gptkb:Valeant_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|